Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: HIV Infections
Interventions: Fleet Enema, tap water enema, Normosol-R enema; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Clostridium Difficile Infection
Interventions: VP20621, Placebo; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 42
States / cities: Modesto, California • Palm Desert, California • Sacramento, California + 39 more

Conditions: HIV Infection, Sexually Transmitted Infection
Interventions: HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package, Handout about HIV PrEP options available at the site, Standard-of-care HIV PrEP counseling from qualified study staff; Drug · Behavioral
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • The Bronx, New York

Conditions: HIV Infections
Interventions: Digital Health Companion (mobile App); Behavioral
Lead sponsor: WV Health Right, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Chronic Hepatitis B
Interventions: FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 1 more

Conditions: HIV Infection, Cardiovascular Disease Risk
Interventions: Pravastatin, Lisinopril; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 40 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV Infections
Interventions: Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 7
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 4 more

Conditions: Sexually Transmitted Diseases, Risk Behavior
Interventions: The MISTERS Intervention for Post Jail Release Men; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: HIV Prevention, Sexually Transmitted Diseases, Pre-Exposure Prophylaxis
Interventions: HOME Study intervention, Control; Behavioral
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions: Panzyga, 10% Intravenous Solution, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 5 more

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more

Conditions: Herpes Zoster
Interventions: Personalized letter, Flyer advertisement, Newspaper press release; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 60 Years and older
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Johnson City, Tennessee • Manchester, Tennessee • Murfreesboro, Tennessee

Conditions: Lung Diseases, Bronchitis, Chronic
Interventions: Avelox (Moxifloxacin, BAY12-8039), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 1,404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 11
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more

Conditions: HIV Infections, Substance Use Disorders
Interventions: PrEPsteps, Digital pill, Truvada; Behavioral · Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boylston, Massachusetts

Conditions: HIV Infections
Interventions: Multivitamins-Multiples of RDA, Multivitamins-Single RDA; Dietary Supplement
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
Interventions: IgPro20; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Atlanta, Georgia • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: HIV Infections
Interventions: BufferGel, PRO 2000/5 Gel, Placebo gel; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Family-Based Risk Reduction Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Human Immunodeficiency Virus
Interventions: Pharmacy Delivered PrEP Intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fungal Infections
Interventions: Micafungin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 4 Months to 16 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 9 more

Conditions: Influenza, Human, Influenza, Human Flu
Interventions: Core letter signed by Surgeon General, Core letter signed by the Director of the National Vaccine Program, Core letter signed by Surgeon General + implementation prompt, Core letter signed by SG + enhanced implementation prompt; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 66 Years and older
Enrollment: 228,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza, Virus Diseases
Interventions: H2N2 1960 AA ca recombinant vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Surgical Site Infection, Antibiotic Prophylaxis
Interventions: Antibiotics; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke, Acute
Interventions: Telestroke; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Edina, Minnesota

Search by objective public record fields.

Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

Cardiovascular Prevention for Persons With HIV

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

An STD Prevention Intervention for Men Newly Released From Jail

HOME Study: a Combination Support Package to Increase Uptake of PrEP and HIV/STI Testing

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

Family-based HIV Prevention for Adolescent Girls

Pharmacy-based Pre-exposure Prophylaxis

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

Mail Outreach To Increase Vaccination Acceptance Through Engagement

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

The Role of Guideline-adherent Perioperative Antibiotic Administration and the Risk of Surgical Site Infections After Non-cardiac Surgery.

Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic